Getinge Customer Research
The design of the IABP SHOCK II trial has several limitations. We still need contemporary data to determine the role of IABP therapy in cardiogenic shock from Acute MI.
124 Customers Surveyed
411 Data Points Collected
13 Published TechFacts
4 Published Charts
Getinge Customer Fact
Zenaida Carbon believes that using inotropes with IABP therapy should be done with caution as their mechanism of action may negate the positive effects of IABP therapy and therefore limit the balloon pumps effectiveness since they negatively affect the myocardial oxygen consumption.
Getinge Website Getinge Website